OR WAIT null SECS
The ICH is publishing its long-awaited guidelines on how to conduct clinical monitoring in trial management. Sponsors and CROs can integrate existing and emerging technologies while transforming their reactive oversight strategies to an RBM approach using these steps.
Five Steps to Ensuring Existing Technology Meets the Next-generation RBM Standard
This month, ICH publishes its long-awaited guidelines on how to conduct clinical monitoring in trial management.
An earlier consultative draft said: “The sponsor should develop a systematic, prioritized, risk-based approach to monitoring clinical trials… A combination of on-site and centralized monitoring activities may be appropriate…”
Trial sponsors and CROs can expect plenty of tough questions to be posed about whether their current technology platform can really support the next iteration of RBM. But don’t assume that your old technology platform is ready for the scrapheap and that investments in a completely new system are needed.
Sponsors and CROs can integrate existing and emerging technologies and transform their reactive oversight strategies to a more proactive RBM approach. The result? Compliance with evolving guidelines while reducing trial time and costs 15-20% – a win-win for all concerned.
New (and Old) Technologies Will Drive the Future
The average clinical trial currently uses as many as seven separate data collection systems. To get a complete picture of risk that also applies a holistic approach to RBM efforts, stakeholders will need to incorporate data from all these sources – as well as critical endpoint data.
But to meet the new demands on RBM created by industry expectations and ICH guidelines, sponsors and CROs will need to enhance existing systems as well as add new technology-driven functionality that includes integration, analytics and Key Risk Indicators (KRIs). This can be accomplished in five easy steps – steps well-worth taking when you consider the benefits.
Although implementing the next generation of RBM technologies will require a significant change in the way organizations think about monitoring and mitigating risk in the trial environment, sponsors and CROs that take the time now to update their systems and transform their approach to risk management will gain significant efficiencies in time and cost savings while they enhance their ability to manage risk. There’s no reason to wait. Sponsors and CROs who adopt the benefits of centralized risk based monitoring can begin reaping the benefits and gaining a competitive advantage even before the ICH addendum goes into effect this month.
By Brion Regan, Product Manager, eClinical Insights, ERT